港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,741.969

+85.0485.13%

漲家數：7

跌家數：1

平家數：- -

市盈率：- -

高：1,761.822

開：1,650.408

低：1,631.718

收：1,656.921

資料載入中...

士澤生物醫藥（上海）有限公司藥品申請臨牀試驗默示許可獲受理

瑞博生物港交所遞表小核酸藥物龍頭企業有望登陸資本市場

泰格醫藥獲易方達基金增持37.21萬股每股作價約26.19港元

藥明康德獲融資買入1.47億元，近三日累計買入5.83億元

據華爾街日報：美國食品藥品監督管理局（FDA）要求疫苗生產商諾瓦瓦克完成新一輪臨牀試驗，以推進延遲推出的新冠病毒疫苗。

【石藥集團(01093.HK)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准】石藥集團(01093.HK)發佈公告，本集團自主研發的化學1類新藥SYH2068注射液(雙鏈小幹擾RNA (si RNA)藥物)(該產品)已獲得中華人民共和國國家藥品監督管理局批准，可以在中國開展臨牀試驗。

石藥集團(01093)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准

易方達基金增持泰格醫藥(03347)37.21萬股每股作價約26.19港元

智通财经网

康臣藥業：收到SK-09片臨牀試驗批准通知書

藥明康德(02359)4月25日斥資2000.58萬元回購34.93萬股A股

康臣藥業(01681.HK)治療腎臟疾病藥物於中國獲批開展臨牀試驗

阿斯达克财经

康臣藥業(01681)收到SK-09片的《藥物臨牀試驗批准通知書》

康龍化成04月25日遭主力拋售844萬元

金斯瑞生物科技04月25日主力淨流出1424萬元散戶資金買入

藥明康德(02359)出現大手賣出24.65萬股，成交價$57.3，涉資1.412千萬

阿斯达克财经

基石藥業（蘇州）有限公司藥品申請臨牀試驗默示許可獲受理

港股概念追蹤 | 七部門發文推進醫藥工業數智化轉型 AI製藥展現較大潛力(附概念股)

康龍化成收盤上漲1.58%，滾動市盈率22.88倍，總市值410.41億元

藥明康德(02359)4月24日斥資2000.49萬元回購35.27萬股A股

維亞生物04月24日主力淨流入40萬元散戶資金拋售

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1741.9692,"timestamp":1746173303338,"preClose":1656.921,"halted":0,"volume":37072828,"delay":0,"changeRate":0.051329,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":85.048218,"latestTime":"05-02 16:00:00","open":1650.4075,"high":1761.8217,"low":1631.7175,"amount":965238145,"amplitude":0.078522,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"pbRate":2.028879,"peRate":9.713901,"turnoverRate":0.003122,"increases":6,"decrements":1,"flats":1,"marketCap":371791222272,"floatMarketCap":162796354560},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1761.8217,"amplitude":0.078522,"preClose":1656.921,"low":1631.7175,"pbRate":"2.028879","latestPrice":1741.9692,"volume":37072828,"delay":0,"open":1650.4075,"prevYearClose":1395.7731,"prevWeekClose":1649.561,"prevMonthClose":1656.921,"prevQuarterClose":1941.338,"fiveDayClose":1658.129,"twentyDayClose":1941.338,"sixtyDayClose":1437.019,"secType":"PLATE","market":"HK","turnoverRate":0.003122,"peRate":9.713901,"marketCap":371791222272,"floatMarketCap":162796354560,"timestamp":1746173303338,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530248331","title":"士澤生物醫藥（上海）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530248331","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530248331?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，士泽生物医药（上海）有限公司、士泽生物医药（苏州）有限公司联合申请药品“XS228细胞注射液”，获得临床试验默示许可，受理号CXSL2500121。士泽生物医药（上海）有限公司，成立于2021年，位于上海市，是一家以从事专业技术服务业为主的企业。主要股东信息显示，士泽生物医药（上海）有限公司由士泽生物医药（苏州）有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","161726","BK1576","399441","BK1583"],"gpt_icon":0},{"id":"2530410672","title":"瑞博生物港交所遞表 小核酸藥物龍頭企業有望登陸資本市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2530410672","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530410672?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 09:32","pubTimestamp":1745717567,"startTime":"0","endTime":"0","summary":"根据招股书，瑞博生物目前有六款自研siRNA药物处于临床试验阶段，涉及七种适应症，其中四款进入2期临床试验；另有超过20个临床前资产持续推进中。血栓性疾病已成为全球主要死因之一，全球四分之一死亡与血栓性疾病相关。截止目前，全球尚未批准任何siRNA药物用于治疗慢性乙型肝炎。瑞博生物作为国内最早专注小核酸药物开发的企业之一，建立了强大的全球知识产权组合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","03347","BK1574","BK1141","01477","BK1191","BK1583"],"gpt_icon":0},{"id":"2530105812","title":"泰格醫藥獲易方達基金增持37.21萬股 每股作價約26.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530105812","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530105812?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 08:32","pubTimestamp":1745713920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，4月22日，易方达基金增持泰格医药（03347）37.21万股，每股作价26.185港元，总金额约为974.34万港元。增持后最新持股数目为770.37万股，持股比例为6.26%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-27/doc-ineuqcqi7921881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK1141","BK0216","LU1146622755.USD","03347","300347","BK1576","BK0174","LU1820825898.SGD","BK1583","BK0077"],"gpt_icon":0},{"id":"2530070197","title":"藥明康德獲融資買入1.47億元，近三日累計買入5.83億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530070197","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530070197?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 08:02","pubTimestamp":1745625759,"startTime":"0","endTime":"0","summary":"4月25日，沪深两融数据显示，药明康德获融资买入额1.47亿元，居两市第51位，当日融资偿还额2.63亿元，净卖出11536.85万元。最近三个交易日，23日-25日，药明康德分别获融资买入2.15亿元、2.21亿元、1.47亿元。融券方面，当日融券卖出5.75万股，净卖出4.46万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504260820209745aecb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504260820209745aecb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","LU2125910500.SGD","02359","LU2242644610.SGD","BK1141","LU0052750758.USD","LU0708995583.HKD","LU1046422090.SGD","LU2045819591.USD","BK1583","LU0320764599.SGD"],"gpt_icon":0},{"id":"2530164849","title":"據華爾街日報：美國食品藥品監督管理局（FDA）要求疫苗生產商諾瓦瓦克完成新一輪臨牀試驗，以推進延遲推出的新冠病毒疫苗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530164849","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530164849?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 03:22","pubTimestamp":1745608922,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7884860a095da688d55e8f59fb0acbc9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159646","BK1583","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2530818993","title":"【石藥集團(01093.HK)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准】石藥集團(01093.HK)發佈公告，本集團自主研發的化學1類新藥SYH2068注射液(雙鏈小幹擾RNA (si RNA)藥物)(該產品)已獲得中華人民共和國國家藥品監督管理局批准，可以在中國開展臨牀試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530818993","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530818993?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 19:27","pubTimestamp":1745580475,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK)发布公告，本集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA (si RNA)药物)(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25192749891416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1008478684.HKD","LU0501845795.SGD","LU1226287875.USD","LU1226288253.USD","03347","LU0067412154.USD","LU1993786604.SGD","IE0008369823.USD","BK4139","BK1515","BK4505","BK1521","SG9999004220.SGD","BK1191","LU0072913022.USD","IE00B543WZ88.USD","01093","IE00B031HY20.USD","IE00BZ08YR35.GBP","BK4585","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU0140636845.USD","LU0880133367.SGD","LU1226287792.SGD","LU1960683339.HKD","IE0008368742.USD","BK1141","LU1951186391.HKD","BK1583","IE00BZ08YT58.USD","LU1152091168.USD","LU1226288170.HKD","RNA","BK4588","LU1807302812.USD","BK1576","IE00B5MMRT66.SGD","LU1226287529.USD"],"gpt_icon":0},{"id":"2530189536","title":"石藥集團(01093)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530189536","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530189536?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 19:22","pubTimestamp":1745580178,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主研发的化学1类新药SYH2068注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面优于同类型si RNA产品，展现出药物作用效果持久、安全性好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1583","LU1226287792.SGD","LU1152091168.USD","BK4588","LU0880133367.SGD","01093","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0501845795.SGD","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1515","LU1226288170.HKD","LU1226287875.USD","LU1807302812.USD","BK1576","BK4585","BK1521","LU0072913022.USD","LU0140636845.USD","03347","LU1226288253.USD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","LU0067412154.USD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","BK4505","RNA","IE0008368742.USD","BK4139","BK1141","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2530899551","title":"易方達基金增持泰格醫藥(03347)37.21萬股 每股作價約26.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530899551","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530899551?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 18:50","pubTimestamp":1745578200,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月22日，易方达基金增持泰格医药(03347)37.21万股，每股作价26.185港元，总金额约为974.34万港元。增持后最新持股数目为770.37万股，持股比例为6.26%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-25/doc-ineuksvt1916276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK1576","LU1146622755.USD","BK1141","03347","BK1583","LU1820825898.SGD","BK0216","BK0174","300347","BK0028"],"gpt_icon":0},{"id":"2530903570","title":"康臣藥業：收到SK-09片臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903570","media":"格隆汇","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903570?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 17:00","pubTimestamp":1745571654,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨康臣药业(01681.HK)发布公告，公司已收到中国国家药品监督管理局签发的有关SK-09片的《药物临床试验批准通知书》。SK-09片为一类化学新药。根据披露，足细胞损伤相关肾脏疾病是一类以肾小球足细胞损伤为主要病理改变的肾脏疾病，包括糖尿病肾病、局灶节段性肾小球硬化、微小病变肾病等。患者常因得不到及时有效的治疗，最终进展为终末期肾病(ESRD)，对患者本人、家庭及社会医疗造成沉重负担。目前临床上缺乏针对足细胞保护的靶向疗法，SK-09片的临床研发有望为肾脏病患者提供更为精准有效的治疗新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042517005494e23a18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042517005494e23a18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1191","BK1606","BK1576","01681","BK1583","03347"],"gpt_icon":0},{"id":"2530702829","title":"藥明康德(02359)4月25日斥資2000.58萬元回購34.93萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530702829","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530702829?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:53","pubTimestamp":1745571218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年4月25日该公司斥资人民币2000.58万元回购34.93万股A股，回购价格为每股人民币56.83-57.79元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","02359","LU2045819591.USD","BK1576","LU1997245177.USD","LU0708995583.HKD","LU0052750758.USD","LU0320764599.SGD","603259","159982","LU1046422090.SGD","LU2125910500.SGD","LU2495084118.USD","LU0456842615.SGD","LU2242644610.SGD","LU2488822045.USD","BK1583","LU1997245094.SGD","399300","BK0216","BK1141"],"gpt_icon":0},{"id":"2530908783","title":"康臣藥業(01681.HK)治療腎臟疾病藥物於中國獲批開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530908783","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530908783?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:48","pubTimestamp":1745570880,"startTime":"0","endTime":"0","summary":"康臣药业(01681.HK) 公布，已收到国家药品监督管理局签发有关“SK-09”片的《药物临床试验批准通知书》。据介绍，相关药物用于足细胞损伤相关肾脏疾病(糖尿病肾病、局灶节段性肾小球硬化及微小病变肾病等)的治疗。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220720140431349_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220720140431349_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436034/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1141","BK1583","BK1606","01681","03347","BK1576"],"gpt_icon":0},{"id":"2530777099","title":"康臣藥業(01681)收到SK-09片的《藥物臨牀試驗批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2530777099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530777099?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:45","pubTimestamp":1745570700,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)公布，公司已收到中国国家药品监督管理局签发的有关SK-09片的《药物临床试验批准通知书》，SK-09片用于足细胞损伤相关肾脏疾病(糖尿病肾病、局灶节段性肾小球硬化及微小病变肾病等)的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","03347","BK1141","BK1191","BK1583","BK1576","BK1606"],"gpt_icon":0},{"id":"2530039079","title":"康龍化成04月25日遭主力拋售844萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530039079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530039079?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:15","pubTimestamp":1745568940,"startTime":"0","endTime":"0","summary":"04月25日, 康龙化成股价跌0.29%，报收13.68元，成交金额7577万元，换手率1.87%，振幅2.92%，量比0.86。康龙化成今日主力资金净流出844万元，连续3日净流出，上一交易日主力净流出587万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为64.29%，平均跌幅为2.38%。该股近5个交易日上涨11.42%，主力资金累计净流出1078万元；近20日主力资金累计净流出7902万元，其中净流出天数为10日。该股主力净额占比0.21%，港股市场排名2633/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170131a46690e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170131a46690e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1141","BK1576"],"gpt_icon":0},{"id":"2530903614","title":"金斯瑞生物科技04月25日主力淨流出1424萬元 散戶資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903614","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903614?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:15","pubTimestamp":1745568906,"startTime":"0","endTime":"0","summary":"04月25日, 金斯瑞生物科技股价跌1.25%，报收11.06元，成交金额1.16亿元，换手率0.48%，振幅3.21%，量比0.72。金斯瑞生物科技今日主力资金净流出1424万元，上一交易日主力净流入165万元。该股近5个交易日上涨6.12%，主力资金累计净流出2823万元；近20日主力资金累计净流出92万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425165901a4669016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425165901a4669016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","HK0000320223.HKD","BK1141","BK1583","HK0000306701.USD","HK0000320264.USD","BK1576","01548"],"gpt_icon":0},{"id":"2530974096","title":"藥明康德(02359)出現大手賣出24.65萬股，成交價$57.3，涉資1.412千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2530974096","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530974096?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:08","pubTimestamp":1745568480,"startTime":"0","endTime":"0","summary":"[大手成交]药明康德(02359)在下午04:08出现大手卖出，成交量为24.65万，成交价为港币$57.3，涉资1.412千万。至目前为止，股价跌1.122%，今日最高价为$59.0，而最低价为$56.85，总成交量为1.039千万股，总成交金额港币$6.009亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2504258478/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","02359","LU0052750758.USD","LU1997244956.HKD","LU1997245094.SGD","LU0456842615.SGD","BK0216","LU0320764599.SGD","LU2242644610.SGD","LU1997245177.USD","LU0708995583.HKD","LU1046422090.SGD","BK1583","LU2488822045.USD","LU2495084118.USD","603259","BK1576","LU2125910500.SGD","LU2045819591.USD"],"gpt_icon":0},{"id":"2530802929","title":"基石藥業（蘇州）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530802929","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530802929?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 12:28","pubTimestamp":1745555312,"startTime":"0","endTime":"0","summary":"4月25日，据CDE官网消息，基石药业（苏州）有限公司、无锡药明合联生物技术有限公司联合申请药品“注射用CS5001”，获得临床试验默示许可，受理号CXSL2500169。基石药业（苏州）有限公司，成立于2016年，位于苏州市，是一家以从事研究和试验发展为主的企业。主要股东信息显示，基石药业（苏州）有限公司由CStone Pharm  Holding Limited持股100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425123710974480c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425123710974480c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","03347","BK1574","BK1576","BK1583","02616","BK1161"],"gpt_icon":0},{"id":"2530918358","title":"港股概念追蹤 | 七部門發文推進醫藥工業數智化轉型 AI製藥展現較大潛力(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530918358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530918358?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 07:17","pubTimestamp":1745536620,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月24日，国家卫健委等七部门联合印发《医药工业数智化转型实施方案》。《方案》提出，到2030年，规上医药工业企业基本实现数智化转型全覆盖，数智技术融合创新能力大幅提升，医药工业全链条数据体系进一步完善，医药工业数智化转型生态体系进一步健全。AI有望重塑传统制药范式，为新药研发带来更多可能性。目前，多数头部AI制药企业可以将药物发现效率提升50%以上，有足够的动力将现有药物发现流程逐步AI化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1576","03759","02359","LU2242644610.SGD","LU2045819591.USD","LU0708995583.HKD","BK1583","01477","HSTECH","02158","BK1518","BK1574","LU0320764599.SGD","YANG","LU0052750758.USD","BK4614","BK1617","BK1189","LU1046422090.SGD","LU2125910500.SGD","BK1141"],"gpt_icon":1},{"id":"2529670338","title":"康龍化成收盤上漲1.58%，滾動市盈率22.88倍，總市值410.41億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529670338","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529670338?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 17:44","pubTimestamp":1745487847,"startTime":"0","endTime":"0","summary":"4月24日，康龙化成今日收盘23.08元，上涨1.58%，滚动市盈率PE达到22.88倍，创15天以来新低，总市值410.41亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.83倍，行业中值53.44倍，康龙化成排名第16位。截至2024年年报，共有71家机构持仓康龙化成，其中基金71家，合计持股数21607.39万股，持股市值58.17亿元。最新一期业绩显示，2024年年报，公司实现营业收入122.76亿元，同比6.39%；净利润17.93亿元，同比12.01%，销售毛利率34.24%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/24174449831917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03759","BK1141","300759","BK0216","BK1576"],"gpt_icon":0},{"id":"2529678042","title":"藥明康德(02359)4月24日斥資2000.49萬元回購35.27萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529678042","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529678042?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 16:47","pubTimestamp":1745484445,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年4月24日该公司斥资人民币2000.49万元回购35.27万股A股，回购价格为每股人民币56.13-57.67元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","LU2125910500.SGD","LU1997245094.SGD","BK0216","BK1141","LU1997244956.HKD","LU0456842615.SGD","LU0052750758.USD","LU2045819591.USD","LU0708995583.HKD","LU1046422090.SGD","159982","LU2488822045.USD","603259","BK1583","LU2495084118.USD","399300","LU2242644610.SGD","LU0320764599.SGD","LU1997245177.USD","02359"],"gpt_icon":0},{"id":"2529676067","title":"維亞生物04月24日主力淨流入40萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529676067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529676067?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 16:16","pubTimestamp":1745482561,"startTime":"0","endTime":"0","summary":"04月24日, 维亚生物股价涨0.67%，报收1.51元，成交金额541万元，换手率0.17%，振幅6.00%，量比1.73。维亚生物今日主力资金净流入40万元，上一交易日主力净流出0万元。该股近5个交易日上涨5.59%，主力资金累计净流入9万元；近20日主力资金累计净流出1038万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165944a46517ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165944a46517ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","01873"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}